PTJ
CMPX icon

Paul Tudor Jones’s Compass Therapeutics CMPX Stock Holding History

Paul Tudor Jones’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$197K Buy
90,044
+1,113
+1% +$3.29K ﹤0.01% 3337
2026
Q1 		$470K Buy
+88,931
New +$513K ﹤0.01% 2860

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Paul Tudor Jones's CMPX Position: Q2 2026 in Review

Paul Tudor Jones increased its Compass Therapeutics (CMPX) stake by 1.3% in Q2 2026, buying an estimated $3.29K and bringing the position to 90,044 shares worth $197K. The position accounts for ﹤0.01% of the portfolio, ranked #3337.

Paul Tudor Jones first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $470K in Q1 2026. 213 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Paul Tudor Jones held 90,044 shares of Compass Therapeutics worth $197K as of Q2 2026.
  • Paul Tudor Jones bought 1,113 Compass Therapeutics shares in Q2 2026, an estimated $3.29K.
  • Compass Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3337 holding.
  • Paul Tudor Jones first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Paul Tudor Jones's Compass Therapeutics position peaked at $470K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.